{"entity":{"id":"roginolisib","kind":"drug","name":"Roginolisib","aka":["IOA-244"],"tldr":"Roginolisib is an oral pi3k inhibitor from iOnctura, in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.","summary":"Roginolisib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by iOnctura, in non-small-cell lung cancer, small-cell lung cancer. A phosphoinositide 3-kinase inhibitor: the name stem -lisib marks a small molecule that blocks PI3K signalling. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of roginolisib","url":"https://clinicaltrials.gov/search?intr=roginolisib"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["ionctura"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06879717"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"modality":"Oral PI3K inhibitor","mechanism":"A phosphoinositide 3-kinase inhibitor: the name stem -lisib marks a small molecule that blocks PI3K signalling.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/roginolisib/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"company":[{"id":"ionctura","kind":"company","name":"iOnctura","route":"/companies/ionctura/"}],"trial":[{"id":"nct06717126","kind":"trial","name":"A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma","route":"/trials/nct06717126/"},{"id":"nct06879717","kind":"trial","name":"A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients","route":"/trials/nct06879717/"}]}}